International Journal for Multidisciplinary Research (IJFMR)
E-ISSN: 2582-2160 ● Website: www.ijfmr.com ● Email: editor@ijfmr.com

Advancing Neonatal Care: Management & Approaches to Reduce Mortality

Smita Nayak[1], Shubham Rasal[2]

[1]Professor, H.O.D., Pharmaceutics, Pharmaceutical Quality Assurance, Gahlot Institute of Pharmacy
[2]Master of Pharmacy Student., Pharmaceutical Quality Assurance, Gahlot Institute of Pharmacy

Abstract:
Neonatal disorders encompass a wide range of medical conditions that affect newborns, often leading to significant morbidity and mortality. Globally, over one million infants succumb in the first twenty-four hours of life, making the first week of life the most common time-period for neonatal mortality. Premature birth, birth complications (birth asphyxia/trauma), newborn infections, and congenital malformations are the primary causes of death among neonates, accounting for nearly 4 out of every 10 fatalities in children under the age of five. In 2023, the first 28 days of life accounted for nearly half (47%) of all deaths in children under the age of five. Thus, this represents a critical time in life that calls for enhanced, high-quality intrapartum and neonatal care. This review article provides a comprehensive overview of the most prevalent neonatal disorders, including Spina bifida, Perinatal asphyxia, Fetal alcohol spectrum disorder, Hirschsprung's disease. The etiology, pathophysiology, clinical presentation, and diagnostic approaches for each condition have been discussed in this review. Furthermore, the article highlights the latest advancements in therapeutic strategies and management protocols aimed at improving neonatal outcomes. Through an extensive review of current literature, this article aims to inform healthcare professionals about the best practices and emerging trends in the management of neonatal disorders, ultimately contributing to enhanced care and survival rates for this vulnerable population.

Keywords: Neonate, Spina Bifida, Perinatal asphyxia, Fetal alcohol spectrum disorder, Hirschsprung's disease.

Introduction:

The word 'neonate' means newborn and includes the first 28 days of life when rapid changes are occurring. As a neonate, the baby undergoes numerous changes as it learns to adapt to extra-uterine life. Its physiological systems, including the lungs and the immune system are far from fully developed and need extra protection from possible sources of infections[1].

Despite advancements in perinatal care, neonatal disorders remain a leading cause of infant morbidity and mortality worldwide. Conditions such as respiratory distress syndrome, neonatal jaundice, sepsis, and congenital anomalies pose significant challenges for clinicians and caregivers. Between 1990 and 2023, there was about 50% decrease in neonatal fatalities recorded worldwide. In India, the prevalence of early neonatal mortality has declined from 3% in 2005 to 2.1% in 2019–2021[2].

The complexity of neonatal disorders necessitates a multi-disciplinary approach to diagnosis, treatment, and management. Early detection and prompt intervention are crucial in mitigating adverse outcomes and improving the long-term health of affected infants. In recent years, there have been substantial

advancements in medical technology, pharmacotherapy, and neonatal care protocols, which have enhanced our ability to manage these conditions effectively. Several international agencies are involved in monitoring neonatal mortality worldwide, employing various methodologies to collect, analyze, and disseminate data. These include….

1. World Health Organization (WHO)

WHO collects data on neonatal mortality through national health information systems, demographic and health surveys, and vital registration systems. They collaborate with countries to improve data quality and reporting. WHO's Global Health Observatory provides data on neonatal mortality and trends. The WHO also supports The Every Newborn Action Plan (ENAP), which aims to reduce preventable newborn deaths[3].

2. United Nations Children's Fund (UNICEF)

UNICEF gathers data through Multiple Indicator Cluster Surveys (MICS) and other national surveys. They work with governments to enhance data collection methods and coverage. UNICEF's Data and Analytics section offers detailed statistics on neonatal mortality. They also support initiatives like the Global Strategy for Women's, Children's, and Adolescents' Health.

This review article aims to provide a comprehensive examination of the most common neonatal disorders, exploring their etiology, pathophysiology, clinical manifestations, and current management strategies. The authors seek to provide up-to-date resource on best practices and emerging trends in neonatal care. A thorough understanding of these disorders and their management can help in better support for health and development of newborns, ultimately contributing to improved survival rates and quality of life for this vulnerable population. Some of the commonly encountered neonatal disorders are briefly discussed herein[4].

1. Spina Bifida:

Spina bifida (SB) is a congenital neural tube defect (NTD) that results from incomplete spinal column closure during embryonic development. Spina bifida is a birth defect in which the vertebral column is open, often with spinal cord involvement. Spina bifida aperta, also known as open spina bifida, is a type of neural tube defect where there is a visible, open lesion on the back through which the spinal cord and meninges protrude. This condition is characterized by the incomplete closure of the neural tube during embryonic development, resulting in an exposed spinal cord. There are two main subtypes of spina bifida aperta:

1. **Myelomeningocele**: This is the most common and severe form of spina bifida aperta. In myelomeningocele, both the spinal cord and the meninges (the membranes that cover the brain and spinal cord) protrude through the open part of the spine, forming a sac on the back. This can result in significant neurological impairments, including paralysis and loss of sensation below the affected area, as well as bladder and bowel dysfunction.
2. **Meningocele**: In this less severe form of spina bifida aperta, only the meninges protrude through the open part of the spine, forming a sac filled with cerebrospinal fluid. The spinal cord itself remains in place, and neurological impairments are usually less severe compared to myelomeningocele. However, some individuals may still experience complications[5].

Both forms of spina bifida aperta require medical intervention, often including surgical repair shortly after birth, to protect the spinal cord and prevent further damage. Below figure represents types of Spina Bifida.

Figure 2 : Types of Spina Bifida



Management:

The optimum course of treatment for neonates with spina bifida is multidisciplinary, involving a combination of surgical, medical, and supportive interventions. The primary goals are to protect the neural tissue, prevent infection, and manage complications to improve the child's quality of life.[6]

1. Prenatal Care and Diagnosis:

Prenatal Screening: Screening tests such as maternal serum alpha-fetoprotein (AFP) and detailed ultrasound examinations can detect spina bifida during pregnancy.

Fetal MRI: This imaging technique can provide detailed information about the severity and location of the defect.

Prenatal Counseling: Parents should receive counseling about the diagnosis, potential outcomes, and treatment options[6].

2. Prenatal Surgery:

Fetal Surgery: In some cases, prenatal surgery to repair the spina bifida defect can be performed. This can reduce the risk of complications such as hydrocephalus and improve neurological outcomes. The procedure involves closing the spinal defect in utero, typically between 19 and 26 weeks of gestation.

3. Immediate Postnatal Care:

Neonatal Intensive Care: Immediate care after birth involves protecting the exposed neural tissue, often with sterile dressings and antibiotic prophylaxis to prevent infection.

4. Surgical Intervention:

Postnatal Surgery: Within the first 24-48 hours of life, surgery is usually performed to close the defect and cover the exposed spinal cord. This helps prevent infection and further damage to the neural tissue.

Ventriculoperitoneal Shunt: Many infants with spina bifida develop hydrocephalus, requiring the placement of a shunt to drain excess cerebrospinal fluid and relieve pressure on the brain[7].

5. Multidisciplinary Management:

Neurosurgery: Ongoing care for neurological complications and monitoring of shunt function.

Orthopaedics: Management of musculoskeletal abnormalities, including clubfoot, scoliosis, and hip dislocations.

Urology: Assessment and management of bladder and bowel dysfunction, often involving clean intermittent catheterization and medications to manage neurogenic bladder.

Physical Therapy: Early intervention with physical and occupational therapy to improve mobility, strength, and functional independence.

Nutrition and Growth: Monitoring and support for proper nutrition and growth, addressing feeding difficulties if present.

Developmental Pediatrics: Regular developmental assessments and early intervention services to address cognitive and developmental delays[8].

Perinatal asphyxia:

Perinatal asphyxia, also known as birth asphyxia, is a serious medical condition that occurs when a newborn baby does not receive enough oxygen during delivery or shortly after birth. This can happen due to various reasons such as prolonged labor or delivery, umbilical cord compression or prolapse, placental abruption, fetal distress, maternal medical conditions, such as hypertension or diabetes[9].

Perinatal asphyxia can cause severe and potentially life-threatening complications, including:

Brain damage: Lack of oxygen can lead to brain damage, which can result in long-term developmental delays, cognitive impairment, and physical disabilities.

Hypoxic-ischemic encephalopathy (HIE): This is a type of brain damage caused by a lack of oxygen and blood flow to the brain[10].

Respiratory distress: Newborns may experience respiratory distress, which can lead to breathing difficulties and the need for mechanical ventilation.

Cardiovascular problems: Perinatal asphyxia can also cause cardiovascular problems, such as heart failure and arrhythmias[11].

Multi-organ failure: In severe cases, perinatal asphyxia can lead to multi-organ failure, which can be life-threatening.

Early recognition and prompt medical intervention are crucial in preventing or minimizing the severity of perinatal asphyxia. The approaches for monitoring fetal health include….

Fetal monitoring: Continuous monitoring of the baby's heart rate and movement during labor[12].

Umbilical cord blood gas analysis: Analysis of the baby's blood gas levels to determine the severity of asphyxia.

Neuroimaging: Imaging tests, such as ultrasound or MRI, to assess brain damage[13].

Treatment:

Resuscitation: Immediate resuscitation efforts, including chest compressions and ventilation, to restore oxygenation and circulation.

Supportive care: Providing oxygen therapy, mechanical ventilation, and other supportive measures to help the baby recover.

Neuroprotection: Medications and other interventions to reduce the risk of brain damage and promote recovery[14].

Fetal alcohol spectrum disorder:

Prenatal alcohol exposure (PAE) is a leading cause of preventable mental disability and birth defects in the western world. Fetal alcohol spectrum disorders (FASD) refers to all alcohol-related neurodevelopmental abnormalities and birth malformations, that are caused by PAE. Growth deficiencies, physical anomalies, neurocognitive and behavioral difficulties, and heightened susceptibility to mental health issues and other comorbidities are all parts of this spectrum of disorders. There is no cure for FAS; it is a persistent disorder. Avoiding alcohol while pregnant is a possibility to avoid this condition[15]. On this scale, fetal alcohol syndrome is the most serious condition. Among the additional conditions covered by FASD are:

Table No. 1. Types of Fetal alcohol spectrum disorders

SR.NO	CONDITION	SYMPTOMS
1)	Partial fetal alcohol syndrome (pFAS)	Altered facial features such as small eyes (microphthalmia), shortened palpebral fissure (the distance between the eyelids). thin upper lip, Small jaw or chin, flat nose; growth and development delays; neurological, behavioural & sensory problems
2)	Alcohol related neurodevelopment disorder (ARND)	Impulsivity; inattentiveness; difficulties with judgment and academic performance.
3)	Alcohol related birth defects (ARBD)	Physical birth defects, or abnormalities affecting specific body components, such as renal, bone, eye, and heart problems.
4)	Neurobehavioral disorder associated with prenatal alcohol exposure (ND-PAE)	Behavioral problems like violent tantrums, difficulty in planning & organizing, memory & learning deficits; emotional, sensory & motor problems[16].

Management and treatment:

Level 1: Raising public awareness through campaigns and other broad strategies.

Public health campaigns that support and encourage women's health in general may increase knowledge of PAE/FASD. More specific efforts include public education campaigns that promote healthy, alcohol-free pregnancies, booklets, and warning labels on alcohol-related products.

Level 2: Brief counselling with women and girls of reproductive age

Prevention of PAE and FASD has been effectively carried out by discussing alcohol use and its related hazards with women of childbearing age during preconception conversations about reproductive health. For adult and adolescent women who are not pregnant, Screening, Brief Intervention and Referral to Treatment (S-BIRT) lowers the risk of PAE, especially after multiple sessions of intervention[17].

Level 3: specialized prenatal support

Alcohol abuse during pregnancy may be treated to reduce the risk of continuing PAE and to improve the health of the fetus. Pregnant women at high risk of alcohol consumption drink less when they receive case

management from a social worker or nurse, which includes problem identification, plan implementation and monitoring, and motivational interviewing—an evidence-based method for supporting behavior change. Furthermore, intensive, specialized home-visiting therapies for high-risk pregnant women not only prevent new occurrences of FASD but also enhance mother and child outcomes. Enhancing nutrition for mothers and decreasing smoking and domestic abuse could potentially enhance the well-being of children in present and next deliveries.

Level 4: specialized postnatal support

Home visits by medical experts or lay supporters to high-risk mothers during the postpartum period improves child outcomes and lower the chances of PAE in subsequent pregnancies. In order to use a FASD prevention strategy, local policies and practices must be taken into account. The needs of the mother and the child are supported by innovative programs, which acknowledge the links between alcohol use by women, parenting, familial factors, and the development of a child. For preventive initiatives to be implemented effectively, strong cross-cultural and community collaborations, as well as an acceptance of cultural knowledge systems and leadership, are essential. While addressing the structural and systemic variables that encourage prenatal alcohol usage, stigma mitigation is crucial[18].

Hirschsprung's disease:

Hirschsprung's disease is a condition that affects the large intestine (colon) and causes problems with passing stool. It is an uncommon congenital condition that affects one in 3,500–5,000 live newborns[19]. It is caused by the absence of ganglion cells (nerve cells) in the bowel, which are necessary for the muscles to contract and move stool through the colon. Symptoms typically appear shortly after birth and can include a swollen abdomen, vomiting, constipation, and failure to pass meconium (the baby's first stool) within 48 hours of birth[20].

Diagnosis is usually made through a combination of physical examination, imaging tests (such as X-rays or contrast enemas), anorectal manometry (a test that measures how well the rectum and anus are working), and a rectal biopsy to confirm the absence of ganglion cells. The primary treatment is surgical, involving the removal of the affected portion of the colon[21]. This surgery can be done in one or two stages, and the goal is to pull through the healthy, ganglion-cell-containing section of the colon to the anus. Understanding the genetic basis of HSCR has advanced significantly in the last few years because of developments in genome-wide genotyping and next-generation sequencing technology[22].

Management and Treatment:

Patients with enterocolitis related to Hirschsprung's disease are treated using a variety of techniques. Rectal irrigations, oral hydration, and oral antibiotics (metronidazole) can all be used in the outpatient environment to treat Grade 1, or possibly even HAEC. Rectal irrigations are intended to assist remove any impediment by washing away any retained faeces. Large sized rubber catheters are typically employed to administer them 2-4 times daily until the effluent is clean[23].

When a patient has Grade 2 (definite HAEC), they must be managed in an inpatient setting. They are typically kept Nil Per Os (NPO) and receive intravenous (IV) antibiotics (metronidazole) along with rectal irrigations and broad-spectrum antibiotic therapy. To rule out infections (Clostridioides difficile, Salmonella, Shigella, Rotavirus) that may be involved and create a similar presenting symptomatology, patients should have stool tests. Management in grade 3 primarily remains the same as in grade 2. These patients, however, are extremely sick and frequently require treatment equivalent to that of an intensive

care unit, nasogastric decompression, and maybe surgical intervention in the form of proximal bowel diversion[24].

Conclusion:

Parents and healthcare professionals face several difficulties when it comes to neonatal illnesses and disorders. Improving outcomes and minimizing the burden of newborn health issues requires early diagnosis, timely management, and comprehensive care. We may expect improved diagnosis, treatment, and preventive strategies as medical technological and scientific advances develop, ensuring a healthier start for every newborn. Education and awareness play an essential role in educating parents and other caregivers with the knowledge they need to offer their beautiful little ones the best care possible during this vulnerable stage of life. A crucial area of pediatric medicine is the treatment of diseases and disorders of the newborn, which necessitates ongoing monitoring, prompt detection, and comprehensive therapy. The very first 28 days of life are a fragile newborn phase that poses a special set of difficulties for parents and medical professionals. Because of their rapid growth and development at this time, neonates are especially exposed to a variety of health problems. Ultimately, the most vulnerable members of society—our newborns—may have a healthier future thanks to our combined efforts to comprehend, prevent, and treat neonatal conditions and illnesses. Together, we can significantly decrease the incidence of newborn diseases and create the conditions for future generations to have healthier, happier beginnings[25].

References:

1. Kahle KT, Klinge PM, Koschnitzky JE, Kulkarni AV, MacAulay N, Robinson S, Schiff SJ, Strahle JM. Paediatric hydrocephalus. Nature Reviews Disease Primers. 2024;10(1):25-35.
2. Tov AB, Lubetzky R, Mimouni FB, Alper A, Mandel D. Trends in neonatology and pediatrics publications over the past 12 years. Acta Paediatrica. 2007;96(7):1080-2.
3. Dessì A, Cesare Marincola F, Masili A, Gazzolo D, Fanos V. Clinical metabolomics and nutrition: the new frontier in neonatology and pediatrics. BioMed research international. 2014;23(1):943-88.
4. Kumari R, Margaret B, Shetty S. Risk factors for neonatal death in India: A retrospective case control study. Journal of Neonatal Nursing. 2024;33(2)21-29.
5. Mitchell LE, Adzick NS, Melchionne J, Pasquariello PS, Sutton LN, Whitehead AS. Spina bifida. The Lancet. 2004;20(2):1885-95.
6. Mohd-Zin SW, Marwan AI, Abou Chaar MK, Ahmad-Annuar A, Abdul-Aziz NM. Spina bifida: pathogenesis, mechanisms, and genes in mice and humans. Scientifica. 2017;(1):5364827.
7. Copp AJ, Adzick NS, Chitty LS, Fletcher JM, Holmbeck GN, Shaw GM. Spina bifida. Nature reviews Disease primers. 2015;30(1):1-8.
8. Fattuoni C, Palmas F, Noto A, Fanos V, Barberini L. Perinatal asphyxia: a review from a metabolomics perspective. Molecules. 2015;20(4):7000-16.
9. Morales P, Bustamante D, Espina-Marchant P, Neira-Peña T, Gutiérrez-Hernández MA, Allende-Castro C, Rojas-Mancilla E. Pathophysiology of perinatal asphyxia: can we predict and improve individual outcomes. EPMA Journal. 2011;20(2):211-30.
10. Jacobs MM, Phibbs RH. Prevention, recognition, and treatment of perinatal asphyxia. Clinics in perinatology. 1989;16(4):785-807.
11. Bruckner M, Lista G, Saugstad OD, Schmölzer GM. Delivery room management of asphyxiated term and near-term infants. Neonatology. 2021;118(4):487-99.

12. Kaminen-Ahola N. Fetal alcohol spectrum disorders: Genetic and epigenetic mechanisms. Prenatal diagnosis. 2020;40(9):1185-92.
13. Król M, Skowron P, Skowron K, Gil K. The Fetal Alcohol Spectrum Disorders—An Overview of Experimental Models, Therapeutic Strategies, and Future Research Directions. Children. 2024;11(5):531.
14. Jones KL, Streissguth AP. Fetal alcohol syndrome and fetal alcohol spectrum disorders: a brief history. The Journal of Psychiatry & Law. 2010;38(4):373-82.
15. Scott S, Sher J. Effect of alcohol during pregnancy: a public health issue. The Lancet Public Health. 2023;8(1):e4-5.
16. Popova S, Charness ME, Burd L, Crawford A, Hoyme HE, Mukherjee RA, Riley EP, Elliott EJ. Fetal alcohol spectrum disorders. Nature reviews Disease primers. 2023;9(1):202-35.
17. Broccia M, Munch A, Hansen BM, Sørensen KK, Larsen T, Strandberg-Larsen K, Gerds TA, Torp-Pedersen C, Kesmodel US. Heavy prenatal alcohol exposure and overall morbidities: A Danish nationwide cohort study. The Lancet Public Health. 2023;8(1):e36-46.
18. Rescorla FJ, Morrison AM, Engles D, West KW, Grosfeld JL. Hirschsprung's disease: evaluation of mortality and long-term function in 260 cases. Archives of Surgery. 1992 1;(8):934-42.
19. Klein M, Varga I. Hirschsprung's disease—recent understanding of embryonic aspects, etiopathogenesis and future treatment avenues. Medicina. 2020;56(11):611-45.
20. Yang X, Bayat V, DiDonato N, Zhao Y, Zarnegar B, Siprashvili Z, Lopez-Pajares V, Sun T, Tao S, Li C, Rump A. Genetic and genomic studies of pathogenic EXOSC2 mutations in the newly described disease SHRF implicate the autophagy pathway in disease pathogenesis. Human molecular genetics. 2020;29(4):541-53.
21. Ambartsumyan L, Smith C, Kapur RP. Diagnosis of Hirschsprung disease. Pediatric and Developmental Pathology. 2020;23(1):8-22.
22. Stensrud KJ, Emblem R, Bjarmaland K. Late diagnosis of Hirschsprung disease—patient characteristics and results. Journal of pediatric surgery. 2012;47(10):1874-9.
23. Granström AL, Ludvigsson JF, Wester T. Clinical characteristics and validation of diagnosis in individuals with Hirschsprung disease and inflammatory bowel disease. Journal of Pediatric Surgery. 2021 Oct;56(10):1799-802.
24. De Lorijn F, Reitsma JB, Voskuijl WP, Aronson DC, Ten Kate FJ, Smets AM, Taminiau JA, Benninga MA. Diagnosis of Hirschsprung's disease: a prospective, comparative accuracy study of common tests. The Journal of pediatrics. 2005;146(6):787-92.
25. Tobon F, Reid NC, Talbert JL, Schuster MM. Nonsurgical test for the diagnosis of Hirschsprung's disease. New England Journal of Medicine. 1968;278(4):188-94.